ArticleJournal of pain research2026
Genetic Evidence for Immune Cell-Lipid Mediation Pathways Linked to Esophageal Cancer and Associated Throat/Chest Pain Phenotypes.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Previous studies showed complex associations between immune cells and esophageal cancer (EC). EC-related pain is closely linked to immune dysregulation and abnormal lipid metabolism, but their synergistic regulatory mechanisms remain unclear. This study aimed to investigate causal relationships between immune cell traits and EC, explore plasma lipids' mediating role, supplement genetic evidence for core immune factors-lipids-pain associations, and provide targets for EC's combined " Antineoplastic-analgesic" intervention. Methods: Genome-wide association study summary data of 731 immune cell traits, 179 lipid metabolites, 998 EC cases, and two pain-related datasets were compiled. Bidirectional MR analysis (with inverse variance weighting, MR-Egger, MR-RAPS, weighted median, weighted mode) was used to infer causal relationships, followed by sensitivity analyses for robustness and FDR correction (Benjamini-Hochberg method) to account for multiple testing. A two-step Mendelian randomization was applied to explore plasma lipids mediating role in the immune cell-EC risk link. Results: This study identified 24 immune cell phenotypes and 14 plasma lipids suggestive causal associations with EC risk. Mediation analysis revealed that HLA DR on CD33dim HLA DR+ CD11b+ affected EC risk via Phosphatidylcholine (18:0_22:6) levels, with a suppression ratio of -82.15%, indicating an exploratory indirect effect that partially offsets the primary protection. Similarly, Phosphatidylcholine (O-18:1_20:4) exhibited a suggestive suppression effect (-10.38%) on the association between SSC-A on CD8+ T cell and EC risk. Furthermore, CD3 on HLA DR+ T cells showed a negative association with both pain-related datasets. CD33 on basophils and SSC-A on CD8+ T cells showed a positive association. Sensitivity analyses showed no significant abnormalities. Conclusion: This study systematically identified immune cell phenotypes causally associated with EC and highlighted key lipid mediators underlying these effects. The core immune cell phenotypes and lipids are not only associated with EC risk but also show consistent genetic associations with typical EC-related pain symptoms, suggesting the existence of a co-regulatory network. These findings provide new insights into the mechanism and combined intervention of EC-related pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.